This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e74. Learning Objective-Upon completion of this activity, successful learners will be able to identify the best therapy for chronic hepatitis C (HCV) genotype 3 patients with and without cirrhosis.
C hronic hepatitis C virus infection (HCV) represents a chronic liver condition that may lead to end-stage liver disease with cirrhosis and hepatocellular carcinoma. 1 The advent of direct-acting antiviral drugs (DAAs) has completely changed the outlook of HCV. Viral cure has become possible with treatments that last 12 to 24 weeks and are devoid of side effects. The efficacy of DAA-based therapy depends on patient-related factors such as cirrhosis, but also on viral genotype. Randomized clinical trials (RCTs) indicate that current regimens result in sustained virologic response (SVR) in more than 90% of patients with genotype 1. 2, 3 However, the evidence base for DAA therapies in genotype 3 is less extensive than for genotype 1. In addition, treatment efficacy appears to be lower in genotype 3 patients, particularly in treatment-experienced patients with cirrhosis. 4 The expansion of DAAs prompted the Food and Drug Administration in 2013 to allow single-arm trials that lack formal placebo arms but instead use historical controls as a comparator. 5 This has resulted in an uneven trial landscape with multiple trials focusing on individual regimens. Key agents used in HCV genotype 3 patients are sofosbuvir, combined with ribavirin, daclatasvir, or velpatasvir. The comparative efficacy of individual combinations largely is unknown, mainly because of the paucity of headto-head trials, although that information is necessary to steer guideline development and clinical decision making.
Our aim was to assess the comparative efficacy of all DAA regimens for HCV genotype 3 using a network metaanalysis and to determine whether addition of ribavirin to DAAs improves treatment efficacy.
Methods
We conducted a systematic review and network metaanalysis according to an a priori written protocol. We used Preferred Reporting Items for Systematic Reviews and network meta-analysis guidelines for this purpose. 6 
Systematic Review
We performed a systematic search to identify studies in HCV genotype 3 patients treated with DAAs. Together with a medical librarian we designed the search strategy for the PubMed, Embase, and Web of Science databases, and conducted the final search on March 15, 2016 (Supplementary File 1) . To include all available data we performed a manual search of abstract books of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases conferences in 2015. Two researchers (B.R.R.Z.A. and F.A.C.B.) independently screened articles in a dualpronged approach: screening by title and abstract and full-text screening. Disagreements were resolved by a third researcher (W.K.). We included studies with the following: patients older than 18 years with HCV genotype 3, and RCTs, prospective clinical trials, and/or real-life studies with at least 1 DAA. We excluded the following studies: (1) with no results specified for HCV genotype 3, (2) no SVR was reported, or (3) studies involving acute hepatitis C-infected patients.
Outcomes, Data Extraction, and Risk of Bias Assessment
The primary outcome was the mean estimated probability of SVR per studied regimen. SVR was defined as an undetectable HCV RNA level 12 weeks after cessation of treatment. One author (B.R.R.Z.A.) extracted study characteristics and intention-to-treat SVR data per regimen and entered this in a structured electronic database (Castoredc, Amsterdam, the Netherlands). A second researcher cross-checked all entered data (F.A.C.B.). Two authors (F.A.C.B. and B.R.R.Z.A.) independently assessed the quality of studies using the Cochrane Collaboration risk of bias tool. 7 Disagreements were resolved by a third researcher (W.K.).
Statistical Analysis
We conducted the network meta-analysis using Bayesian Markov Chain Monte Carlo (MCMC) methods. We used a random-effects model with noninformative priors comparable with the network meta-analysis model of treatment response of Goring et al. 8 Direct and indirect evidence for all studied regimens were combined to estimate the probability of SVR per studied regimen, with a 95% equal tail credible interval (95% CrI), by means of a logistic regression model. We included the following fixed factors in the model: type of DAA, ribavirin (binary), duration of therapy (12, 16 , or 24 weeks), presence of cirrhosis as a prognostic factor for efficacy, and interaction of ribavirin and cirrhosis. As a random effect we added the study, to model the positive correlation between study arms from the same study and to reflect deviations from the mean effects caused by specific study and patient characteristics. The additional effect of ribavirin was estimated by means of an odds ratio (OR). The MCMC approach was based on 3 chains and updated with 200,000 simulations, thinning 1 per 10 and a burn-in of 10,000. We checked that the MCMC procedures had reached convergence by visually inspecting the history trace plots and the autocorrelation plots for irregularities.
To identify the most effective regimen, we focused on a subset of regimens recommended in guidelines, authorized in the market or under evaluation by regulatory authorities. [9] [10] [11] We ranked these regimens according to estimated SVR rates. 12 Furthermore, we performed conventional meta-analyses per regimen to assess inconsistency and fit of the model. Heterogeneity was assessed by the estimated between-study variation s 2 of the network meta-analysis and by I 2 of the meta-analyses per regimen.
Sensitivity Analyses
We performed 4 sensitivity analyses to assess the reliability and robustness of the model and to increase homogeneity of the population: (1) we included studies with a low risk of bias and studies with only a high risk of bias on blinding of participants because SVR is an objective outcome measure, (2) we included only regimens available in the market or under evaluation by regulatory authorities, (3) we excluded studies with patients with decompensated cirrhosis, and (4) we excluded studies with human immunodeficiency virus/HCV co-infected patients. Because the effect of ribavirin is expected to be lower when added to a regimen consisting of 2 DAAs, we performed an additional analysis to assess the effect of ribavirin when combined with 2 DAAs. Treatment status (naive or experienced) was not included in the model because of limited available data specified on both cirrhosis status and treatment status per patient. To explore the effect of this choice, we performed an analysis with treatment status instead of cirrhosis in the model. All analyses were performed in WinBUGS 1.4.3 (London, United Kingdom) and R version 3.0.1 (R2winbugs, Vienna, Austria). 13, 14 The WinBUGS syntax is available in Supplementary File 2.
Results

Treatment Landscape
Of the 2167 identified articles, we selected 26 articles (21 full text, 5 abstracts) describing 27 studies (16 RCTs, 6 single-arm studies, and 5 observational cohorts) ( Figure 1) . Overall, the 27 studies included 3415 patients, consisting of 2294 (67%) treatment-naive patients and 1088 (32%) patients with cirrhosis. Eleven combinations of DAAs were studied, duration of therapy varied between 8 and 24 weeks with or without addition of ribavirin (Table 1 and Supplementary File 3) . We excluded the 8-week regimens from our network meta-analysis because only a few patients were treated with 8-week regimens (n ¼ 13). There was variation in the number of patients studied per regimen; range, 7-868 patients. We designed 3 networks to connect regimens, but the majority of regimens were connected in networks 1 and 2 ( Figure 2 ).
Sustained Virologic Response in Noncirrhotic Patients
Twenty-two different regimens were studied in noncirrhotic HCV genotype 3 patients ( Figure 3A) . The highest SVR rates were estimated for sofosbuvir þ daclatasvir þ ribavirin for 24 weeks (98.9%; 95% CrI, 97.6-99.6), sofosbuvir þ velpatasvir þ ribavirin for 12 weeks (98.8%; 95% CrI, 97.5-99.6), and sofosbuvir þ daclatasvir þ ribavirin for 16 weeks (98.0%; 95% CrI, 95.7-99.2).
We ranked a subset of the regimens (the clinically relevant regimens as based on guidelines and clinical practice, shown in Supplementary File 4 and marked grey in Figure 2 ) from 1 to 6. In this subset, the regimen sofosbuvir þ velpatasvir þ ribavirin for 12 weeks had the highest probability to be ranked first, sofosbuvir þ velpatasvir for 12 weeks to be ranked second, and sofosbuvir þ daclatasvir þ ribavirin for 12 weeks to be ranked third, and so forth (Supplementary File 4A). Based on the ranking we estimated the differences in SVR rates between treatments (Table 2 ). Sofosbuvir þ velpatasvir þ ribavirin for 12 weeks reached higher SVR rates than all other recommended regimens in the subset (range, 2%-12% higher SVR). In contrast, sofosbuvir þ velpatasvir for 12 weeks, sofosbuvir þ daclatasvir þ ribavirin for 12 weeks, and sofosbuvir þ peginterferon þ ribavirin for 12 weeks had similar SVR rates. Sofosbuvir þ ribavirin for 24 weeks had a similar estimated SVR to sofosbuvir þ daclatasvir for 12 weeks; both were inferior to other reported regimens.
Sustained Virologic Response in Cirrhotic Patients
In total, 19 different regimens were studied in cirrhotic HCV genotype 3 patients. The highest SVR rates Figure 3B ). Ranking and comparison of the subset of clinically important regimens resulted in sofosbuvir þ velpatasvir for 24 weeks to be ranked first, sofosbuvir þ daclatasvir þ ribavirin for 24 weeks to be ranked second, and sofosbuvir þ velpatasvir þ ribavirin for 12 weeks to be ranked third, and so forth (Supplementary File 4B) . However when we compared the regimens in the subset with each other, similar SVR rates were estimated for the first 3 ranked regimens (Table 3) . Sofosbuvir þ velpatasvir for 12 weeks resulted in a 7% lower SVR, whereas sofosbuvir þ peginterferon þ ribavirin for 12 weeks resulted in a 16% lower SVR than sofosbuvir þ velpatasvir þ ribavirin for 12 weeks. Sofosbuvir þ ribavirin for 24 weeks was inferior to all other regimens, with 22% to 40% lower SVR estimates.
Effect of Ribavirin
In patients without cirrhosis the OR of ribavirin was 2.6 (95% CrI, 1.3-4.7), and in patients with cirrhosis the OR was 4.5 (95% CrI, 2.5-7.7). We also performed an analysis with only studies including 2 DAAs AE ribavirin. We found an OR of 6.5 (95% CrI, 1.9-17.8) in patients without cirrhosis and an OR of 3.9 (95% CrI, 2.0-7.0) in patients with cirrhosis. Ribavirin had a significant additional effect, even when used with 2 DAAs in both cirrhotic and noncirrhotic patients.
Fit of the Model and Sensitivity Analyses
To assess the consistency and fit of the model we performed direct meta-analyses of regimens and the results were largely similar to our network meta-analysis, with the exception of 2 regimens: sofosbuvir for 12 weeks and sofosbuvir þ velpatasvir for 24 weeks. These 2 regimens were studied only once in 7 and 12 patients respectively. 15, 23 With regard to heterogeneity, the majority of meta-analyses per regimen had an I 2 of less than 50%, except for 3 regimens (sofosbuvir þ ribavirin for 12 weeks, sofosbuvir þ ribavirin for 16 weeks [patients without cirrhosis], and sofosbuvir þ velpatasvir [100 mg] for 12 weeks [patients with cirrhosis]) (Supplementary File 5) . The network meta-analysis resulted in an overall estimated s 2 of 0.78 (95% CrI, 0.27-1.73), suggesting between-study variation in the SVR rates. We performed 4 sensitivity analyses (Supplementary File 6) . For the first sensitivity analysis we excluded studies with a high risk of bias, except studies with only a high risk of bias on blinding of participants (Supplementary File 7) . The overall estimated SVR rates were lower and the 95% CrI was wider; SVR for sofosbuvir þ daclatasvir regimens decreased whereas sofosbuvir þ velpatasvir regimens had similar SVR In case of placebo, these patients were excluded from SVR calculations.
b
The treatment arms with 8 weeks' duration were excluded from the analysis.
estimates as in the primary analysis. Results were consistent with the primary analysis in the other 3 sensitivity analyses. We also built a model in which cirrhosis was replaced by treatment status (treatment-naive vs treatment-experienced). Again, the estimated SVR and ranking were largely similar to the overall results (Supplementary File 8).
Discussion
In this systematic review and network meta-analysis, we combined data from 27 studies to establish a hierarchy of available treatment regimens for HCV genotype 3. The key finding was that sofosbuvir-velpatasvir regimens achieve the highest efficacy in HCV genotype 3: sofosbuvir þ velpatasvir þ ribavirin for 12 weeks in noncirrhotic patients and sofosbuvir þ velpatasvir (without ribavirin) for 24 weeks or with ribavirin for 12 weeks in cirrhotic patients, although similar estimated SVR rates can be reached with sofosbuvir þ daclatasvir þ ribavirin for 24 weeks. In patients without cirrhosis, regimens such as sofosbuvir þ peginterferon þ ribavirin and sofosbuvir þ daclatasvirþ ribavirin for 12 weeks only had a 1% to 4% lower estimated SVR rates, and remain an option for treatment. The advantage of sofosbuvir þ velpatasvir over other regimens is that ribavirin can be omitted in noncirrhotic patients and that it shortens the duration of treatment in cirrhotic patients.
Second, we established the added value of ribavirin (odds ratio, 2.6-4.5), regardless of the presence of cirrhosis. However, it is important to keep in mind that the actual effect of adding ribavirin on SVR rates depends on the efficacy of the backbone regimen: the increase in SVR resulting from ribavirin is highest with regimens that have a lower intrinsic efficacy. A recent review and current American Association for the Study of Liver Diseases guidelines suggest that ribavirin can be dropped from the combination of sofosbuvir þ daclatasvir in noncirrhotic genotype 3 patients. Our data suggest that in this case SVR decreases by 6%. In clinical practice, the effect of ribavirin has to be traded off against both the side-effect profile of Figure 2 . Networks of studies. Evidence network of all DAA-based regimens studied in chronic hepatitis C genotype 3 patients. The thickness of the lines represents the number of studies (connecting lines) or the total number of patients studied (box lines). Within the box, the DAA combination with the duration of treatment (12, 16, or 24 weeks) is visible. Gray regimens are selected for ranking. DCV, daclatasvir; LDV, ledipasvir; OBV, ombitasvir; PR, peginterferon and ribavirin; PTV, paritaprevir/ ritonavir; RBV, ribavirin; SOF, sofosbuvir; TPR, telaprevir; 12, 12 weeks; 16, 16 weeks; 24, 24 weeks; VEL, velpatasvir 100 mg; VEL (25) , velpatasvir 25 mg.
ribavirin and the expected reduction in costs related to the DAA. The review and the guideline recommend use of ribavirin in cirrhosis, which is supported by our data. 9, 41 A third finding was the identification of regimens that clearly are inferior in HCV genotype 3: sofosbuvir þ daclatasvir for 12 weeks and sofosbuvir þ ribavirin for 24 weeks in noncirrhotic patients. Both achieved 5% to 12% lower SVR rates compared with other recommended regimens. In cirrhotic patients, differences in efficacy were more visible: sofosbuvir þ ribavirin for 24 weeks obviously was inferior to other reported regimens (22%-40% lower SVR rates) and should be considered obsolete.
The lack of head-to-head trials is an important issue for guideline developers and physicians, and drives researchers to perform network meta-analyses. 42 In the field of hepatitis C, some network meta-analyses have been performed to assess the relative efficacy of DAAs in HCV genotype 1. 3, 43, 44 Because genotype is an important predictor for response, these results cannot be compared with genotype 3. The technique of network meta-analysis is not only of value in HCV, but has merits for other disease entities such as alcoholic hepatitis or Crohn's disease. [45] [46] [47] Results of network meta-analyses support physicians and guideline developers in decision making, but also can identify treatments that should be compared head-to-head, in our study this could be the first-until fourth-ranked regimens.
Our study had strengths and limitations. We combined all available evidence of DAA regimens for HCV genotype 3 with use of Bayesian statistics. Current guidelines do not rank therapies because formal head-tohead trials are lacking. Our method enables the identification of a hierarchy of therapies for HCV genotype 3. One of the limitations of our study was that results were based on three networks, which were not connected. This forced us to perform an arm-based rather than a comparison-based network meta-analysis. This approach is supported by the literature for HCV, but impedes inconsistency assessment.
8 However, our model produced outcomes similar to the conventional meta-analyses per regimen, which bolsters our conclusions. Furthermore, estimated SVR rates of peginterferon and ribavirin therapy in our study reflect SVR rates in the literature. 48 Another limitation of our network metaanalysis was the risk of conceptual heterogeneity, reflecting differences between trials that may impair comparability. We used several strategies to target heterogeneity: (1) we used a random-effects model (by including a study effect in our model), (2) we have split the analyses for patients with and without cirrhosis, and (3) we performed sensitivity analyses to increase homogeneity, which showed similar results. Moreover, SVR is an objective outcome that decreases the risk of heterogeneity. 49 Many studies in our network analysis have a high risk of bias. Exclusion of these studies in our sensitivity analysis resulted in a similar ranking of regimens, but estimated SVR rates were lower and 95% CrIs were wider. In the real world, SVR rates might be compromised in view of the lower generalizability of trials, but we do not expect that the hierarchy would be affected. Finally, we were not able to assess publication bias formally because the studies per regimen ranged from 1 to 7; nevertheless, we do not expect publication bias because the field of HCV evolves rapidly and trial results are needed for evaluation by regulatory authorities. 7 
Implications for Clinical Practice
The findings of our network meta-analysis can be used to prioritize DAA regimens for HCV genotype 3 patients in guidelines and clinical practice. In patients without cirrhosis we focused on 12-week regimens and 4 regimens had an estimated SVR rate of 95% or higher: sofosbuvir þ velpatasvir þ ribavirin for 12 weeks was the best option, directly followed by sofosbuvir þ velpatasvir, sofosbuvir þ daclatasvir þ ribavirin, and sofosbuvir þ peginterferon þ ribavirin for 12 weeks. Sofosbuvir þ ribavirin for 24 weeks and sofosbuvir þ daclatasvir for 12 weeks were inferior. In patients with cirrhosis, sofosbuvir þ velpatasvir with ribavirin for 12 weeks or without ribavirin for 24 weeks and sofosbuvir þ daclatasvir þ ribavirin for 24 weeks can be recommended. Sofosbuvir þ velpatasvir for 12 weeks had 7% to 10% lower estimated SVR rates compared with other regimens, and therefore can be considered as an alternative instead of a recommended regimen in cirrhotic patients. 9 Sofosbuvir þ ribavirin for 24 weeks was inferior to newer regimens. Our study also showed that ribavirin significantly increased the estimated SVR rates, however, the precise effect was dependent on the actual DAA combination. In clinical practice, choice of treatment may depend on several factors, such as availability and price of DAAs, tolerance of ribavirin, risk of adverse events or drug-drug interactions, and the presence of resistance-associated substitutions.
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